Cost-Effectiveness Analysis of Different Biologic Agents For Ankylosing Spondylitis Treatment In Russia

Fedyaev, D. V.; Derkach, E.V.

doi:10.1016/j.jval.2016.09.1117

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a cost-effectiveness analysis in Finland indicated that secukinumab was less costly and more effective compared to adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab in AS treatment [56]. Also, secukinumab was proved to be the most cost-effective treatment option versus other biologics in AS by numerous researches conducted in Canada [57], Argentina [58], the UK [59], and Russia [60]. Besides the 10 included RCTs, more trials are planned or conducted to further evaluate the efficacy and safety of IL-17A inhibitors in AS.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials

Wang

Zhang

et al. 2021

Clin Rheumatol

View full text Add to dashboard Cite

To assess the efficacy and safety of interleukin (IL)-17A inhibitors in patients with ankylosing spondylitis (AS). PubMed, EMBASE, and Web of Science were searched up to 5 February 2020 for randomized controlled trials (RCTs) that assessed the efficacy and safety of IL-17A inhibitors in patients with AS. We used a meta-analytic approach to perform a random effects analysis or fixed effects analysis according to heterogeneity. Subgroup analyses between studies included medication, time to primary endpoint, and data source. Odds ratios (ORs) or mean differences (MDs) were used to assess the efficacy and safety of IL-17A inhibitors in AS. A total of ten RCTs with 2613 patients were eligible for inclusion in the analysis (six for secukinumab, two for ixekizumab, one for netakimab, and one for bimekizumab). Compared to placebo, IL-17A inhibitors improved ASAS20 response rate (OR = 2.58; p < 0.01) and ASAS40 response rate (OR = 2.80; p < 0.01), and significantly increased the risk of AEs (OR = 1.23; p = 0.03) and nasopharyngitis (OR = 1.72; p < 0.01), but not SAEs (OR = 0.87; p = 0.60). IL-17A inhibitors demonstrated better efficacy in patients with AS in several evaluation indicators. However, the safety of IL-17A inhibitors remains to be further studied in studies with larger sample size and longer follow-up times.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials

Wang

Zhang

et al. 2021

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…This is among the first full-length studies assessing cost-effectiveness of secukinumab 150 mg compared with other biologics. However, other modeling studies have been conducted in different countries such as Canada,34 UK,35,36 Turkey,37 Colombia,38 Bulgaria,39 and Russia;40 which reported similar results. All these studies reported secukinumab to be dominant (more effective and less costly) over anti-TNFs in biologic-naïve as well as biologic-experienced AS population.…”

Section: Discussionmentioning

confidence: 65%

<p>Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland</p>

Purmonen¹,

Puolakka²,

Mishra³

et al. 2019

CEOR

View full text Add to dashboard Cite

This study assesses the cost-effectiveness of secukinumab vs currently licensed biologics for the treatment of ankylosing spondylitis (AS) from the Finnish health care system perspective. Methods: A semi-Markov model compared secukinumab with adalimumab, adalimumab biosimilar, certolizumab pegol, etanercept, etanercept biosimilar, golimumab, and infliximab in a biologic-naïve population over a lifetime horizon. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess the treatment response. Efficacy inputs were obtained from the network meta-analysis, and other model inputs were obtained from the published literature and Finnish sources. Main study outcomes included quality-adjusted life years (QALYs) gained and incremental cost-effectiveness ratio in terms of cost per QALY gained. Robustness of results was confirmed by sensitivity analyses and alternative scenario analyses. Results: Secukinumab achieved highest QALYs (13.1) at lowest expected lifetime cost (€279,872) vs other comparators in biologic-naïve AS patients in the base case analysis, thus it dominated other biologics. Golimumab had a second highest QALYs (12.9) at the total cost of €309,551. Results were sensitive to variation in BASDAI 50 response for secukinumab, baseline Bath Ankylosing Spondylitis Functional Index (BASFI) score across all drugs, change in BASDAI and BASFI scores, and discount rates as observed in the one-way sensitivity analyses. Secukinumab was either dominant or cost-effective treatment in different alternative scenarios. Conclusion: Secukinumab presented itself to be the dominant (ie, less costly and more effective) treatment vs other comparators for the biologic-naïve patients with AS in Finland.

show abstract

“…Several studies from different countries have reported the cost-effectiveness of secukinumab vs other biologics for the treatment of AS (Supplementary Table S14). These include studies from Turkey 37 , Colombia 38 , the UK 39,40 , Bulgaria 41 , and Russia 42 . As these published studies were conducted for different countries, results are not directly comparable to our study.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective

Goeree

Chiva-Razavi

Gunda

et al. 2018

Journal of Medical Economics

View full text Add to dashboard Cite

Aim: To assess the cost-effectiveness of interleukin (IL)-17A inhibitor secukinumab vs the currently licensed biologic therapies in ankylosing spondylitis (AS) patients from a Canadian healthcare system perspective. Methods: A decision analytic model (semi-Markov) evaluated the cost-effectiveness of secukinumab 150 mg compared to certolizumab pegol, adalimumab, golimumab, etanercept and etanercept biosimilar, and infliximab and infliximab biosimilar in a biologic-naïve population, over 60 years of time horizon (lifetime). The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI 50) response rate was used to assess treatment response at week 12. Non-responders or patients discontinuing initial-line of biologic therapy were allowed to switch to subsequent-line biologics. Model input parameters (short-term and long-term changes in BASDAI and Bath Ankylosing Spondylitis Functional Index [BASFI], withdrawal rates, adverse events, costs, resource use, utilities, and disutilities) were obtained from clinical trials, published literature, and other Canadian sources. Benefits were expressed as quality-adjusted life years (QALYs). Cost and benefits were discounted with an annual discount rate of 1.5% for all treatments. Results: In the biologic-naïve population, secukinumab 150 mg dominated all comparators, as patients treated with secukinumab 150 mg achieved the highest QALYs (16.46) at the lowest cost (CAD 533,010) over a lifetime horizon vs comparators. In the deterministic sensitivity analysis, results were most sensitive to changes in baseline BASFI non-responders, BASDAI 50 at 3 months and discount rates. Probabilistic sensitivity analysis showed that secukinumab 150 mg demonstrated higher probability of achieving maximum net monetary benefit vs all comparators at various cost thresholds. Conclusions: This analysis demonstrates that secukinumab 150 mg is the most cost-effective treatment option for biologic-naïve AS patients compared to certolizumab pegol, adalimumab, golimumab, etanercept and etanercept biosimilar, and infliximab and infliximab biosimilar for a lifetime horizon in Canada. Treatment with secukinumab translates into substantial benefits for patients and the healthcare system.

show abstract

Cost-Effectiveness Analysis of Different Biologic Agents For Ankylosing Spondylitis Treatment In Russia

Cited by 4 publications

References 0 publications

Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials

Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials

<p>Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland</p>

Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective

Contact Info

Product

Resources

About